본문 바로가기
KERD
논문KCI 등재

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Miyoung Choi|Dae Won Jun|Seung Up Kim|Jihyun An|Mi Na Kim|Ji Won Han|Jung Hwan Yu|Young-Joo Jin|Hee Yeon Kim|Han Ah Lee|Young Eun Chon
대한간학회 (The korean Association for the Study of the Liver)|2024.10|Clinical and Molecular Hepatology|제30권 제4호|pp. 117-133|DOI 10.3350/cmh.2024.0392

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Meta-analysisNon-alcoholic fatty liver diseaseMagnetic resonance elastographyAdvanced fibrosisVibration-controlled transient elastography

초록

Background/aims: Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF. Methods: Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated. Results: A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa. Conclusions: VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.

Abstract

Background/aims: Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF. Methods: Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated. Results: A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa. Conclusions: VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.

참고문헌 (102)

  1. Teng ML, "Global incidence and prevalence of nonalcoholic fatty liver disease", Clin Mol Hepatol, 29(Suppl), pp.S32~S42 (2023)
  2. Rinella ME, "Nonalcoholic fatty liver disease : a systematic review", JAMA, 313, pp.2263~2273 (2015)
  3. Loomba R, "Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality : a real world analysis of Medicare data", Aliment Pharmacol Ther, 51, pp.1149~1159 (2020)
  4. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : A systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
  5. Vilar-Gomez E, "Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease : A multinational cohort study", Gastroenterology, 155, pp.443~457 (2018)
  6. Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
  7. Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
  8. Regev A, "Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection", Am J Gastroenterol, 97, pp.2614~2618 (2002)
  9. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : Systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
  10. Younossi ZM, "Pathologic criteria for nonalcoholic steatohepatitis : interprotocol agreement and ability to predict liverrelated mortality", Hepatology, 53, pp.1874~1882 (2011)
  11. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
  12. European Association for the Study of the Liver, "E. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update", J Hepatol, 75, pp.659~689 (2021)
  13. Anstee QM, "Noninvasive tests accurately identify advanced fibrosis due to NASH : Baseline data from the STELLAR trials", Hepatology, 70, pp.1521~1530 (2019)
  14. Boursier J, "Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease", J Hepatol, 65, pp.570~578 (2016)
  15. Chan WK, "A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis", Hepatol Int, 9, pp.594~602 (2015)
  16. Furlan A, "Comparison of 2D shear wave elastography, transient elastography, and MR elastography for the diagnosis of fibrosis in patients with nonalcoholic fatty liver disease", AJR Am J Roentgenol, 214, pp.W20~W26 (2020)
  17. Gaia S, "Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis", J Hepatol, 54, pp.64~71 (2011)
  18. Garg H, "Utility of transient elastography(fibroscan)and impact of bariatric surgery on nonalcoholic fatty liver disease(NAFLD)in morbidly obese patients", Surg Obes Relat Dis, 14, pp.81~91 (2018)
  19. Kumar R, "Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease : diagnostic performance and clinicopathological correlation", Dig Dis Sci, 58, pp.265~274 (2013)
  20. Lee MS, "Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease", PLoS One, 12, pp.e0188321~ (2017)
  21. Lupsor M, "Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis", J Gastrointestin Liver Dis, 19, pp.53~60 (2010)
  22. Mahadeva S, "Performance of transient elastography(TE)and factors associated with discordance in non-alcoholic fatty liver disease", J Dig Dis, 14, pp.604~610 (2013)
  23. Lee DH, "A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 55, pp.994~1007 (2022)
  24. Naveau S, "The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD", Obes Surg, 24, pp.1693~1701 (2014)
  25. Oeda S, "Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M", XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease : a multicenter prospective study, 2020, pp.55, 428~440
  26. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
  27. Petta S, "Reliability of liver stiffness measurement in non-alcoholic fatty liver disease : the effects of body mass index", Aliment Pharmacol Ther, 33, pp.1350~1360 (2011)
  28. Petta S, "Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 114, pp.916~928 (2019)
  29. Rosso C, "Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis", Dig Liver Dis, 48, pp.55~61 (2016)
  30. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
  31. Ajmera V, "Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease : A systematic review and meta-analysis of individual participants", Gastroenterology, 163, pp.1079~1089 (2022)
  32. Selvaraj EA, "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD : A systematic review and meta-analysis", J Hepatol, 75, pp.770~785 (2021)
  33. Singh S, "Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease : a diagnostic accuracy systematic review and individual participant data pooled analysis", Eur Radiol, 26, pp.1431~1440 (2016)
  34. Singh S, "Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and meta-analysis of individual participant data", Clin Gastroenterol Hepatol, 13, pp.440~451 (2015)
  35. Kwok R, "Systematic review with meta-analysis : non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
  36. Hashemi SA, "Assessment of transient elastography(FibroScan)for diagnosis of fibrosis in non-alcoholic fatty liver disease : A systematic review and meta-analysis", Caspian J Intern Med, 7, pp.242~252 (2016)
  37. Cao YT, "Accuracy of controlled attenuation parameter(CAP)and liver stiffness measurement(LSM)for assessing steatosis and fibrosis in non-alcoholic fatty liver disease : A systematic review and meta-analysis", EClinicalMedicine, 51, pp.101547~ (2022)
  38. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
  39. Liang Y, "Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease : a pooled analysis of the diagnostic accuracy", BMC Gastroenterol, 20, pp.89~ (2020)
  40. Xiao G, "Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease : A meta-analysis", Hepatology, 66, pp.1486~1501 (2017)
  41. Liang JX, "An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography", J Hepatol, 79, pp.592~604 (2023)
  42. McInnes MDF, "Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies : The PRISMA-DTA statement", JAMA, 319, pp.388~396 (2018)
  43. Reitsma JB, "Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews", J Clin Epidemiol, 58, pp.982~990 (2005)
  44. Argalia G, "Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD", Radiol Med, 127, pp.571~576 (2022)
  45. Barsamian C, "Diagnostic of hepatic fibrosis with the XL probe of the Fibroscan versus biopsies in patients candidates to bariatric surgery", Clin Nutr ESPEN, 37, pp.226~232 (2020)
  46. Chan WK, "Controlled attenuation parameter using the FibroScan®XL probe for quantification of hepatic steatosis for nonalcoholic fatty liver disease in an Asian population", United European Gastroenterol J, 5, pp.76~85 (2017)
  47. Garteiser P, "Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates", JHEP Rep, 3, pp.100381~ (2021)
  48. Imajo K, "Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.908~917 (2022)
  49. Kim JW, "Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease", Quant Imaging Med Surg, 12, pp.1815~1829 (2022)
  50. Lee HW, "Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease", PLoS One, 11, pp.e0157358~ (2016)
  51. Leong WL, "Comparing point shear wave elastography(ElastPQ)and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 35, pp.135~141 (2020)
  52. Okajima A, "Liver stiffness measurement to platelet ratio index predicts the stage of liver fibrosis in non-alcoholic fatty liver disease", Hepatol Res, 47, pp.721~730 (2017)
  53. Sharpton SR, "Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease", Therap Adv Gastroenterol, 14, pp.17562848211050436~ (2021)
  54. Shi YW, "Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages", J Dig Dis, 21, pp.279~286 (2020)
  55. Shima T, "Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography(VCTE)for predicting fibrosis stage of non-alcoholic fatty liver disease", J Gastroenterol, 55, pp.100~112 (2020)
  56. Siddiqui MS, "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.156~163 (2019)
  57. Yang X, "Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease", Lipids Health Dis, 20, pp.27~ (2021)
  58. Yoneda M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease(NAFLD)", Dig Liver Dis, 40, pp.371~378 (2008)
  59. Boursier J, "Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications", Clin Gastroenterol Hepatol, 21, pp.1243~1251 (2023)
  60. Cardoso AC, "The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort", Eur J Gastroenterol Hepatol, 32, pp.231~238 (2020)
  61. Cassinotto C, "Liver stiffness in nonalcoholic fatty liver disease : A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy", Hepatology, 63, pp.1817~1827 (2016)
  62. Chang D, "Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis", Hepatology, 77, pp.546~557 (2023)
  63. Chang PE, "Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore", Singapore Med J, 60, pp.532~537 (2019)
  64. Eddowes PJ, "Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1717~1730 (2019)
  65. Eilenberg M, "Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity", Hepatobiliary Surg Nutr, 10, pp.610~622 (2021)
  66. Ergelen R, "Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease", Eur J Gastroenterol Hepatol, 27, pp.667~671 (2015)
  67. Inadomi C, "Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and noninvasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease", Hepatol Res, 50, pp.682~692 (2020)
  68. Jafarov F, "The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis : a biopsy-proven nonalcoholic fatty liver disease study", Eur J Gastroenterol Hepatol, 32, pp.642~649 (2020)
  69. Lee JI, "Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis", World J Gastroenterol, 25, pp.4959~4969 (2019)
  70. Lee JS, "Comparison of FibroScan-aspartate aminotransferase(FAST)score and other non-invasive surrogates in predicting highrisk non-alcoholic steatohepatitis criteria", Front Med(Lausanne), 9, pp.869190~ (2022)
  71. Mendoza YP, "Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two-dimensional shear wave elastography in nonalcoholic fatty liver disease", Liver Int, 42, pp.102~111 (2022)
  72. Myers RP, "Transient elastography for the noninvasive assessment of liver fibrosis : a multicentre Canadian study", Can J Gastroenterol, 24, pp.661~670 (2010)
  73. Myers RP, "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients", Hepatology, 55, pp.199~208 (2012)
  74. Nogami A, "Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD", Sci Rep, 12, pp.21925~ (2022)
  75. Ooi GJ, "Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity", Int J Obes(Lond), 42, pp.1900~1911 (2018)
  76. Taibbi A, "Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography", Ultrasonography, 40, pp.407~416 (2021)
  77. Vali Y, "Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease(the LITMUS project) : a comparative diagnostic accuracy study", Lancet Gastroenterol Hepatol, 8, pp.714~725 (2023)
  78. Wong VW, "Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease", Gut, 68, pp.2057~2064 (2019)
  79. Yu H, "Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus", Ann Palliat Med, 10, pp.9702~9714 (2021)
  80. Tovo CV, "Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease(NAFLD)", Ann Hepatol, 18, pp.445~449 (2019)
  81. Kosick HM, "A stepwise algorithmic approach and external validation study for noninvasive prediction of advanced fibrosis in nonalcoholic fatty liver disease", Dig Dis Sci, 66, pp.4046~4057 (2021)
  82. Sanyal AJ, "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores", J Hepatol, 78, pp.247~259 (2023)
  83. Armandi A, "Cross-sectional and longitudinal performance of non-invasive tests of liver fibrosis in patients with non-alcoholic fatty liver disease", J Clin Med, 12, pp.650~ (2023)
  84. Noureddin M, "Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis : independent validation of the Agile 3+ and 4 scores", Hepatol Commun, 7, pp.e0055~ (2023)
  85. Petta S, "Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD", Aliment Pharmacol Ther, 46, pp.617~627 (2017)
  86. Petta S, "The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease", Liver Int, 35, pp.1566~1573 (2015)
  87. Troelstra MA, "Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease : The Amsterdam NAFLD-NASH cohort", J Magn Reson Imaging, 54, pp.1937~1949 (2021)
  88. Seki K, "Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease", Hepatol Res, 47, pp.882~889 (2017)
  89. Labenz C, "Predictors of advanced fibrosis in non-cirrhotic nonalcoholic fatty liver disease in Germany", Aliment Pharmacol Ther, 48, pp.1109~1116 (2018)
  90. Pavlides M, "Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity", Liver Int, 37, pp.1065~1073 (2017)
  91. Costa-Silva L, "MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease", Eur J Radiol, 98, pp.82~89 (2018)
  92. Cui J, "Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease : A prospective study", Hepatology, 63, pp.453~461 (2016)
  93. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
  94. Kim JW, "Multiparametric MR index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease", Sci Rep, 10, pp.2671~ (2020)
  95. Loomba R, "Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease : a prospective study", Hepatology, 60, pp.1920~1928 (2014)
  96. Zhang YN, "Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease", Eur Radiol, 32, pp.2457~2469 (2022)
  97. Inada K, "Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 37, pp.1726~1731 (2022)
  98. Cui J, "Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for noninvasive diagnosis of advanced fibrosis in biopsy-proven nonalcoholic fatty liver disease : a prospective study", Aliment Pharmacol Ther, 41, pp.1271~1280 (2015)
  99. Loomba R, "Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD : A prospective study", Am J Gastroenterol, 111, pp.986~994 (2016)
  100. Newsome PN, "FibroScan-AST(FAST)score for the noninvasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
  101. Noureddin M, "MRI-based(MAST)score accurately identifies patients with NASH and significant fibrosis", J Hepatol, 76, pp.781~787 (2022)
  102. Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASH-related fibrosis", Gut, 70, pp.1946~1953 (2021)

관련 논문AI추천

Vibration-controlled transient elastography for significant fibrosis in treatment- naïve chronic hepatitis B patients: A systematic review and meta-analysisDae Won Jun, Eun Hwa Kim, Han Ah Lee, Hee Yeon Kim, Jihyun An, Ji Won Han, Jung Hwan Yu, Mi Na Kim, Miyoung Choi, Seung Up Kim, Young Eun Chon, Young-Joo Jin대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease소영호, Chang Mee Soo, Jang Heejoon, Jang Siwon, Joo Sae Kyung, Kim Won, Lee Dong Ho, Lee Dong Hyeon, Lee Yun Kyu, Park Jeong Hwan거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제6호Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibrationcontrolled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”Vincent Wai-Sun Wong, Yangyue Zhang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis안상봉, 이지은, Choi Miyoung, Cho Yuri, Han Sangsoo, Jun Dae Won, Kang Seong Hee, Lee Bora, Lee Hye Won, Song Do Seon, Yoo Jeong-Ju거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제6호Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibrationcontrolled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”Won Sohn대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis김승업, 전대원, 한지원, Han Ah Lee, Hee Yeon Kim, Ji Hyun An, Jung Hwan Yu, Mi Na Kim, Miyoung Choi, Young Eun Chon, Young-Joo Jin대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호

이 간행물의 다른 논문 (78건)

Congratulatory remarks김원pp. 2-2Preface김승업pp. 3-3PrefaceDae Won Junpp. 4-4Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysisYoung Eun Chon, Miyoung Choi, Ji Won Han, 전대원, Mi Na Kim, Jung Hwan Yu, Young-Joo Jin, Hee Yeon Kim, Han Ah Lee, 김승업, Jihyun An, Gunho Kimpp. 134-146Diagnostic accuracy of the Fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: A systematic review and meta-analysis한지원, 김승업, Han Ah Lee, Young Eun Chon, Hee Yeon Kim, Young-Joo Jin, Jung Hwan Yu, Mi Na Kim, 전대원, Ji Hyun An, Miyoung Choipp. 147-158
원문 보기